Incyte (INCY) Aktsia Kursus

Incyte Corp is primarily active in the biotechnology and pharmaceutical industries.

The main competitors of Incyte Corp in the market are Bristol-Myers Squibb Company, Novartis AG, and Merck & Co., Inc.

Incyte Corp is a leading biopharmaceutical company based in the United States. Founded in 1991, it has established a strong reputation in the field of drug discovery and development. Incyte Corp primarily focuses on the discovery, development, and commercialization of innovative therapies to address various unmet medical needs. Throughout its history, the company has been committed to advancing scientific knowledge, and it has successfully launched several drugs targeting different diseases. With a dedicated team of researchers and professionals, Incyte Corp continues to make significant contributions to the healthcare industry, aiming to improve the lives of patients worldwide.

Incyte Corp has achieved several significant milestones in its history. One notable achievement is the development and approval of its flagship drug, Jakafi® (ruxolitinib), by the U.S. Food and Drug Administration (FDA) in 2011. Jakafi® is the first and only FDA-approved treatment for certain types of rare blood cancers. Additionally, Incyte Corp has made advancements in the field of oncology with the discovery and development of multiple innovative drugs, aiming to improve the lives of patients with various types of cancer. The company continues to expand its pipeline and collaborate with leading research institutions, further establishing itself as a prominent player in the biopharmaceutical industry.

Incyte Corp is primarily present in various countries and regions globally. The company has a widespread presence in the United States, where its headquarters are located in Wilmington, Delaware. Additionally, Incyte Corp has established its significant presence in Europe, including countries such as the United Kingdom, Germany, France, Italy, and Spain. It has also expanded its operations in Asia-Pacific regions like Japan, China, and Singapore. Furthermore, Incyte Corp has been expanding its reach in Latin American countries such as Brazil and Mexico, as well as in Canada. Overall, Incyte Corp has a strong international presence, allowing it to cater to a global market.

Incyte Corp represents values centered around innovation, collaboration, and integrity. The company prioritizes scientific excellence and is dedicated to discovering and developing transformative medicines for patients. Incyte Corp fosters a corporate philosophy that emphasizes the importance of putting patients first, embracing diversity and inclusion, and maintaining high ethical standards. With a focus on research and development, Incyte Corp strives to make a positive impact on the lives of patients and the healthcare industry as a whole.

Analüütikud määravad Incyte aktsiale keskmiseks hinnasihi 128,38 USD (mediaan: 130,00 USD), mis on +12,4 % viimase hinna suhtes. Konsensus põhineb 35 analüütiku hinnangul.

Incyte Analüütikute kurssizihtpunktid 2026

35 analüütikut hindavad praegu Incyte aktsiat: 18 soovitab osta, 17 hoida ja 0 müüa. 2026. aastaks ootavad analüütikud, et Incyte teenib tulu 5,94 B USD ja kasumit aktsia kohta 3,27 USD.

Incyte Analüütikute kurssizihtpunktid 2026

Praeguse kursiga kaubeldakse Incyte aktsiaga 101,61 EUR (114,21 USD) juures.

Incyte aktsia (INCY) on noteeritud 8 börsil, sh: NASDAQ (INCY), London (0J9P.L), SIX (Zürich) (ICY.SW), Frankfurt (ICY.F), München (ICY.MU), Düsseldorf (ICY.DU).

Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and marketing of drugs to help patients with serious diseases. The company is headquartered in Wilmington, Delaware, USA, and operates subsidiaries in Europe and Asia. Its business model is based on developing therapies to combat serious diseases such as cancer, inflammation, and autoimmune diseases through targeted therapy that attacks specific molecules in the body to reduce tumor spread or inflammatory reactions. Incyte Corp has a wide range of products that treat various diseases, with its flagship product being Jakafi® (Ruxolitinib), a drug for treating myelofibrosis and polycythemia vera. It also has a strong pipeline of new drugs in development, including Itacitinib for treating graft-versus-host disease and INCMGA00012 for treating solid tumors. The company is investing in digitization and data analysis to optimize its research and development efforts, and has various business segments including research and development, sales and marketing, clinical studies, and others. It distributes its products directly to clinics and hospitals as well as indirectly through wholesalers and distribution partners, and has formed partnerships with other companies in the industry to enhance research and development and expand global market access. In summary, Incyte Corp is dedicated to discovering, developing, and marketing drugs for patients with serious diseases, with a broad product range, strong partnerships, and a pipeline of new drugs in development. The company is dedicated to using data to improve patient care.

oodatav Incyte käive on 5,94 B USD. See näitaja põhineb praegusel finantsandmetel ja peegeldab ettevõtte äritulemuseid.

oodatav Incyte kasum on 669,64 M USD. Netokasum peegeldab ettevõtte kasumlikkust pärast kõigi kulude mahaarvamist.

Võrdlusarvud hinna ja kasumiga (P/E) Incyte jaoks on praegu 34,93. P/E-suhtarv võrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Incyte aktsia väärtust.

Kursuse ja müügimahu suhe (P/S) Incyte jaoks on praegu 3,94. P/S-suhtarv võrdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismõõdikuna Incyte aktsia jaoks.

Eulpooli kvaliteedinäitaja Incyte jaoks on 6/10.

Incyte ISIN on US45337C1027. ISIN (rahvusvaheline väärtpaberi identifitseerimise number) on väärtpaberite globaalne unikaalne tuvastaja.

Incyte WKN on 896133. WKN (Wertpapierkennnummer) on kuuekohaline saksa väärtpaberi identifitseerimise number.

Incyte ticker on INCY. Ticker-sümbol kasutatakse Incyte aktsiate kauplemiseks börsil.